Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.

about

Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.

Item

http://www.wikidata.org/entity/Q50068063

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Absolute Bioavailability of Bo ...... zed, 2-Period Crossover Study.

@en

Absolute Bioavailability of Bo ...... zed, 2-Period Crossover Study.

@nl

type

Item

label

Absolute Bioavailability of Bo ...... zed, 2-Period Crossover Study.

@en

Absolute Bioavailability of Bo ...... zed, 2-Period Crossover Study.

@nl

prefLabel

Absolute Bioavailability of Bo ...... zed, 2-Period Crossover Study.

@en

Absolute Bioavailability of Bo ...... zed, 2-Period Crossover Study.

@nl

P1476

Absolute Bioavailability of Bo ...... zed, 2-Period Crossover Study.

@en

P2093

Daniela Soriano Pignataro

http://www.w3.org/2001/XMLSchema#string

Kyle Matschke

http://www.w3.org/2001/XMLSchema#string

Poe-Hirr Hsyu

http://www.w3.org/2001/XMLSchema#string

P2860

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Structure, regulation, signaling, and targeting of abl kinases in cancer.

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.

Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.

P31

scholarly article

P356

10.1002/CPDD.396

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29058816

http://www.w3.org/2001/XMLSchema#string